Reference health
Killer Acquisitions
1 of 65 checkable references need attention · checked 2026-09-16
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
35 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1162/105864000567945
The 64 checked references that resolve
resolves10.3386/w25755
Ten Facts on Declining Business Dynamism and Lessons from Endogenous Growth Theory
resolves10.1111/1467-937X.t01-1-00020
The Sale of Ideas: Strategic Disclosure, Property Rights, and Contracting
resolves10.1016/0047-2727(84)90041-0
Dragon-slaying and ballroom dancing: The private supply of a public good
resolves10.1016/j.jpubeco.2012.10.003
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
resolves10.1257/aer.20131176
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
resolves10.1162/REST_a_00431
New Evidence on the Finite Sample Properties of Propensity Score Reweighting and Matching Estimators
resolves10.1111/j.1430-9134.1994.00481.x
R
<scp>acing</scp>
T
<scp>o</scp>
I
<scp>nvest</scp>
? T
<scp>he</scp>
D
<scp>ynamics of</scp>
C
<scp>ompetition in</scp>
E
<scp>thical</scp>
D
<scp>rug</scp>
D
<scp>iscovery</scp>
resolves10.1016/S0169-7218(10)01004-X
Fifty Years of Empirical Studies of Innovative Activity and Performance
resolves10.1016/S0167-6296(02)00126-1
The price of innovation: new estimates of drug development costs
resolves10.1080/13571516.2015.1045744
Do “Reverse Payment” Settlements Constitute an Anticompetitive Pay-for-Delay?
resolves10.2307/2556023
Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins
resolves10.1111/j.1756-2171.2012.00159.x
A Markov‐perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry
resolves10.1086/467257
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
resolves10.1086/261404
The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration
resolves10.1006/jeth.2000.2654
A Note on Price and Quantity Competition in Differentiated Oligopolies
resolves10.1080/13571516.2019.1651151
Event Study Analysis in Cases with Multiple Brand-Generic Reverse-Payment Settlements
resolves10.3386/w22194
Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges
resolves10.2307/2555761
Underinvestment and Incompetence as Responses to Radical Innovation: Evidence from the Photolithographic Alignment Equipment Industry
resolves10.2307/2555791
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
resolves10.1007/s11151-005-1753-7
On Welfare under Cournot and Bertrand Competition in Differentiated Oligopolies
resolves10.1086/691524
Estimating the Innovator’s Dilemma: Structural Analysis of Creative Destruction in the Hard Disk Drive Industry, 1981–1998
resolves10.1016/S0742-3322(04)21005-1
DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY
resolves10.1111/1467-6451.00066
The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry
resolves10.1111/0022-1082.00398
The Market for Corporate Assets: Who Engages in Mergers and Asset Sales and Are There Efficiency Gains?
resolves10.1016/S0167-7187(98)00057-5
Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry
resolves10.2307/1885620
Losses from Horizontal Merger: The Effects of an Exogenous Change in Industry Structure on Cournot-Nash Equilibrium
resolves10.1257/jep.7.3.97
Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
resolves10.1016/j.jfineco.2013.11.001
Firm boundaries matter: Evidence from conglomerates and R&D activity
resolves10.1111/cts.12577
The Current Status of Drug Discovery and Development as Originated in
<scp>United States</scp>
Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development
resolves10.1016/0048-7333(86)90027-2
Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy
The 35 references without a DOI — listed, not checked
no DOI — not checkedEstimating the Cost of New Drug Development: Is It Really $802 Million?
no DOI — not checkedA Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets
no DOI — not checkedref14
no DOI — not checkedAntitrust Limits on Startup Acquisitions
no DOI — not checkedref20
no DOI — not checkedPatent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry
no DOI — not checkedref22
no DOI — not checkedref28
no DOI — not checkedStrategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
no DOI — not checkedHorizontal Mergers and Product Innovation
no DOI — not checkedPay-for-Delay: How Drug Company Pay-Offs Cost Consumers Billions
no DOI — not checkedMarkets for Ownership
no DOI — not checkedAre Me-Too Drugs Justified?
no DOI — not checkedA Framework for Estimating Damages in Reverse Payment Cases
no DOI — not checkedMergers and R&D Diversity: How Much Competition is Enough?
no DOI — not checkedPreemptive Patenting and the Persistence of Monopoly
no DOI — not checkedHow Do Venture Capitalists Make Decisions?
no DOI — not checkedOrganizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms
no DOI — not checkedPaying for Delay: Pharmaceutical Patent Settlement As a Regulatory Design Problem
no DOI — not checkedMonopoly and the Incentive to Innovate When Adoption Involves Switchover Disruptions
no DOI — not checkedref63
no DOI — not checkedref65
no DOI — not checkedref66
no DOI — not checkedref67
no DOI — not checkedref70
no DOI — not checkedConditional Logit Analysis of Qualitative Choice Behavior
no DOI — not checkedref77
no DOI — not checkedThe Effect of Horizontal Mergers: When Firms Compete in Prices and Investments
no DOI — not checkedApproaches to Measure Chemical Similarity: A Review
no DOI — not checkedref83
no DOI — not checkedref91
no DOI — not checkedref97
no DOI — not checkedref98
no DOI — not checkedref99
no DOI — not checkedref100
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-09-16 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.3241707"><img src="https://citestamp.com/citestamped/10.2139/ssrn.3241707/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.3241707)